Peptidic, non-covalent inhibitors of lysosomal cysteine protease cathepsin S (1 and 2) were investigated due to low oral bioavailability, leading to an improved series of peptidomimetic inhibitors. Utilizing phenyl succinamides as the P2 residue increased the oral exposure of this lead series of compounds, while retaining selective inhibition of the cathepsin S isoform. Concurrent investigation of
由于口服
生物利用度低,研究了溶酶体半胱
氨酸
蛋白酶组织蛋白酶S(1和2)的肽类非共价
抑制剂,从而产生了一系列拟肽
抑制剂。使用苯基琥珀
酰亚胺作为P2残基可增加该先导系列化合物的口腔暴露,同时保留对组织蛋白酶S亚型的选择性抑制作用。对P1和P2亚位点的同时研究导致发现了几种有效的和选择性的组织蛋白酶S
抑制剂,这些酶由于消除了饱和脂肪族P2残基而具有良好的药代动力学特性。